Advertisement
Singapore markets close in 4 hours 50 minutes

  • Straits Times Index

    3,289.26
    +23.31 (+0.71%)
     

  • Nikkei

    38,217.20
    +143.22 (+0.38%)
     

  • Hang Seng

    18,856.84
    +319.03 (+1.72%)
     

  • FTSE 100

    8,381.35
    +27.30 (+0.33%)
     

  • Bitcoin USD

    62,863.06
    +1,158.40 (+1.88%)
     

  • CMC Crypto 200

    1,351.69
    +51.59 (+3.97%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • Dow

    39,387.76
    +331.36 (+0.85%)
     

  • Nasdaq

    16,346.26
    +43.46 (+0.27%)
     

  • Gold

    2,359.90
    +19.60 (+0.84%)
     

  • Crude Oil

    79.80
    +0.54 (+0.68%)
     

  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     

  • FTSE Bursa Malaysia

    1,602.76
    +1.54 (+0.10%)
     

  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     

  • PSE Index

    6,569.43
    +26.97 (+0.41%)
     

TCR² Therapeutics to Present at the Needham Healthcare Conference

TCR2 Therapeutics
·2-min read

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, will present an update on Company progress at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021 at 8:00am E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR2 Therapeutics

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR2 Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com